MedPath

Safety and Efficacy of Cisplatin Based Transarterial Chemo-Embolization in Combination with Gemcitabine and Cisplatin for Patients with Unresectable Cholangiocellular Carcinoma

Not Applicable
Conditions
Cholangiocellular Carcinoma
Registration Number
JPRN-UMIN000004776
Lead Sponsor
Chiba University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

1) History of malignant tumor 2) Severe cardiac disease 3) Active infection 4) History of HIV infection 5) Renal dialysis 6) Intracranial tumor 7) Clinically uncontrolled ascites or pleural effusion 8) Clinically severe gastrointestinal bleeding within 4 weeks of the start of treatment 9) Prior history of chemotherapy with gemcitabine and cisplatin

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Safety
Secondary Outcome Measures
NameTimeMethod
Overall Survival (OS) Progression Free Survival (PFS) 1-year Survival Rate 6 months Progression Free Survival Response Rate (RR)
© Copyright 2025. All Rights Reserved by MedPath